Off Label and Experimental Uses for Modafinil

Modafinil has been used off label as a remedy for sedation and fatigue with depression. Illnesses such as fibromyalgia and chronic fatigue syndrome are barely making it on the medical radar as legitimate illnesses but some physicians are treating them with Modafinil. Also myotonic dystrophy, opioid provoked tiredness, spastic cerebral palsy, and Parkinson’s disease are all being treated with Modafinil off label. It has shown to increase friendly behavior and upbeat agreeable moods specifically in those suffering with shift work sleep disorder or SWSD.

There was one eight week double blind study conducted with Modafinil as an option to treat cocaine addiction but the results proved to be uncertain for the most part. There was a lowering of the number of positive urine tests in the group using Modafinil as opposed to the placebo group after the first month, but by the completion of the 2 month study any difference was less note worthy. To make matters even more clouded the Modafinil group apparently had used less cocaine leading up to the beginning of the study. When compared to the sugar pill group, Modafinil did not show any marked decrease in the test subjects craving nor with any self reported use of cocaine. Even the physician’s reports were rated just slightly superior. There was some disapproval from National Addict Advocacy Groups that censured the study researchers for not including negative data in the published after study reporting. There have been studies using Modafinil for weight reduction because of claims that users of the medication seem to find it has a potential as a weight loss treatment due to a loss of appetite.

According to the exclusive UK based Medline records which progress for more than one month showed participants in the studies underwent a weight reduction when evaluated alongside the placebo groups. However, in the prescription literature that accompanies Provigil there is a disclaimer stating there is no noteworthy medicine based distinction in weight reduction in patients treated with Modafinil (Provigil) when compared with Placebo use patients in any controlled research studies. Clinical trials showed that the Modafinil had an effect on weight loss or appetite reduction the same as one would experience with amphetamines. The significant difference was that effective dosage levels of Modafinil to reduce weight did not come with the adverse reaction of a rise in the subject’s heart rate, as you would find with amphetamines. Obviously, the adage where there is smoke there is fire would apply to Modafinil and weight loss.

Physicians that are up to date with pharmacology would know this and in the right circumstances prescribe off label usage of Modafinil to reduce weight in some patients. Modafinil has been used to decrease fatigue and tiredness due to the effect of primary biliary cirrhosis of the liver. This is when the bile ducts within the liver begin to degenerate eventually causing liver failure and is diagnosed primarily in woman. Within two months of commencing treatment with Modafinil, there was a marked improvement in the PBC symptoms according to all data checks and balances with sleep scales. Off label trials have also been conducted in people who have had chemo therapy but experience post treatment intuitive reasoning reduction, sometimes also referred to as unflatteringly as ‘chemobrain’.

A Rochester University study with sixty eight post chemo patients showing symptoms returned momentous results. A research scientist involved in the study said that they were aware of the previous data to rectify attention and memory tribulations in Modafinil test participants and they crossed their fingers that the same results would be apparent in their study participants. Breast cancer patients with post therapy chemobrain did indeed have exciting results when using Modafinil. A study was conducted where neither the researchers nor the test subjects were aware of who was taking what active medication, placebo or Modafinil, among healthy unpaid participants between the ages of 30 to 44. The data showed overall general enhancement in their moods and alertness levels. The three day study featured all the blinding techniques and balances one could imagine for a short duration inpatient trial. 400 mg of Modafinil was given and a placebo directed to the control group. The test resulted in a positive demonstration of Modafinil as a mood enhancing treatment specifically when used in conjunction for regimen resistant depression.